- (R)-MG132
-
- $10.00
-
2026-06-26
- CAS:1211877-36-9
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 1 ton
- (R)-MG-132
-
- $34.00
-
2026-04-28
- CAS:1211877-36-9
- Purity: 99.90%
- Supply Ability: 10g
- (R)-MG-132
-
- $34.00
-
2026-04-28
- CAS:1211877-36-9
- Purity: 99.90%
- Supply Ability: 10g
|
| | (R)-MG132 Basic information |
| Product Name: | (R)-MG132 | | Synonyms: | (R)-MG132;Cbz-L-leu-D-leu-L-leu-H;N-[(Phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-D-leucinamide;MG-132(R);benzyl N-[(2S)-4-methyl-1-[[(2R)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate;MG-132(S,R,S);(S,R,S)-(-)-MG-132;Z-Leu-D-leu-leu-al | | CAS: | 1211877-36-9 | | MF: | C26H41N3O5 | | MW: | 475.62 | | EINECS: | 202-303-5 | | Product Categories: | peptides | | Mol File: | 1211877-36-9.mol |  |
| | (R)-MG132 Chemical Properties |
| Boiling point | 682.0±55.0 °C(Predicted) | | density | 1.073±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 25 mg/ml | | pka | 11.14±0.46(Predicted) | | form | powder | | color | White to off-white | | InChIKey | MQUQNJIRJAJICL-RJGXRXQPSA-N | | SMILES | C(N)(=O)[C@@H](CC(C)C)N(C(=O)[C@H](CC(C)C)NC(OCC1=CC=CC=C1)=O)[C@H](C=O)CC(C)C |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | (R)-MG132 Usage And Synthesis |
| Description | The ubiquitin-proteasome pathway plays an integral role in the selective degradation of intracellular proteins. While important for clearing damaged or mis-folded proteins, this proteolytic pathway also regulates the availability of key proteins involved in the control of inflammatory processes, cell cycle regulation, and gene expression. (R)-MG132 is a potent, reversible, and cell permeable proteasome inhibitor. After treatment for one hour at 100 nM, it inhibits 50% and 31% of proteasome activity in lysates of J558L multiple myeloma cells and EMT6 breast cancer cells, respectively. The (R)-MG132 stereoisomer is a more effective inhibitor of chymotrypsin-like (ChTL), trypsin-like (TL), and peptidylglutamyl peptide hydrolyzing proteasome (PGPH) activities compared to (S)-MG132 (IC50s = 0.22 versus 0.89 μM (ChTL); 34.4 versus 104.43 μM (TL); 2.95 versus 5.70 μM (PGPH), respectively). | | Uses | (R)-MG-132 is a potent, reversible and selective tripeptide aldehyde proteasome inhibitor. | | Uses | (R)-MG132 has been used in ubiquitination assay and is used as a proteasome inhibitor. | | Definition | ChEBI: D-leucinamide, n-[(phenylmethoxy)carbonyl]-l-leucyl-n-[(1s)-1-formyl-3-methylbutyl]- is a peptide. | | Biochem/physiol Actions | MG132 (carbobenzoxy-Leu-Leu-leucinal) is a tri-peptide aldehyde. It possesses antitumor activity and boosts cytostatic/cytotoxic effects of chemo- and radiotherapy. (R)-MG132 is a potent, membrane-permeable proteasome inhibitor. It can inhibit proteasome activity in lysates of J558L multiple myeloma cells and EMT6 breast cancer cells. The (R)-MG132 stereoisomer is a more effective inhibitor of chymotrypsin-like (ChTL), trypsin-like (TL), and peptidylglutamyl peptide hydrolyzing proteasome (PGPH) activities than the (S)-MG132. | | storage | Store at -20°C | | References | [1] D H LEE A L G. Proteasome inhibitors: valuable new tools for cell biologists.[J]. Trends in Cell Biology, 1998, 8 10: 397-403. DOI: 10.1016/s0962-8924(98)01346-4
[2] MICHA MROCZKIEWICZ. Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach[J]. Journal of Medicinal Chemistry, 2010, 53 4: 1509-1518. DOI: 10.1021/jm901619n
[3] YA-JU CHANG. Cyclic Stretch Facilitates Myogenesis in C2C12 Myoblasts and Rescues Thiazolidinedione-Inhibited Myotube Formation[J]. Frontiers in Bioengineering and Biotechnology, 2016, 4 1. DOI: 10.3389/fbioe.2016.00027 |
| | (R)-MG132 Preparation Products And Raw materials |
|